Search the Newsreel

Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a …

Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price

Willdan Group Number of Employees 2026 | Employee Count & Headcount Data

Willdan Group Inc. (WLDN) had approximately 1,850 employees worldwide as of March 2026, marking a 10.8% growth since 2023. The company is actively hiring, with job postings increasing by 73.5% in 2026, though overall employee sentiment is negative and declining. Most employees are based …

CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380

This article provides a comprehensive stock analysis of Celldex Therapeutics Inc (CLDX) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company's fundamentals are considered healthy with significant growth potential, and it is deemed …

Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Celldex Therapeutics Inc (CLDX), listing major shareholders such as Wellington Management Company, LLP and BlackRock Institutional Trust Company, N.A., along with their respective holdings and proportions. It also breaks down shareholder types, institutional shareholding trends over several …

Alldigi Tech Share Price Falls on Q1 Results

Willdan Group Inc (WLDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Willdan Group Inc (WLDN), detailing its market capitalization, P/E ratio, and recent stock performance. It notes that relevant data for business segments and regional profit contributions have not yet been disclosed by the company. The article does …

Willdan Group Inc (WLDN) Cash Flow

This article provides a detailed historical cash flow statement for Willdan Group Inc (WLDN), covering quarterly financial data from FY2012Q1 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with specific components like capital expenditures and changes in working capital. The …

Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2

Celldex Therapeutics, Inc. (DUS:TCE2) generated €1.32 million in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment, a significant decrease from €6.78 million in the previous year. The United States was the company's largest regional contributor, matching the segment's revenue.

Willdan Group Inc (WLDN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Willdan Group Inc.'s (WLDN) shareholder structure, detailing major institutional holdings and shareholder types. It lists top shareholders like BlackRock and Vanguard, categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund), and presents institutional shareholding trends over several quarters. …

Alldigi Tech consolidated net profit rises 21.69% in the June 2026 quarter

Alldigi Tech posts 21.7% profit surge in Q1FY27, declares ₹30 dividend

Willdan Group Inc (WLDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Willdan Group Inc (WLDN), detailing its current price momentum, support and resistance levels, and readings from various technical indicators and moving averages. While the stock is trading within a range suitable for swing trading, most indicators and …

WLDN|Willdan Group Inc|Price:72.650|Chg%:-0.700

Willdan Group Inc.'s stock (WLDN) closed at $72.65, down 0.95%. The company, a provider of professional, technical, and consulting services, exhibits healthy fundamentals and significant growth potential, although its stock market performance has been weak recently. Analysts currently rate the stock as "Buy" with …

How will UK banks and their customers be affected by the Iran war?

Some of the UK's biggest high street banks are set to have grown their profits over the first half of the year, but experts said there could be warnings over the risk of more bad loans as the Iran war pushes up the cost …

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Willdan Group (WLDN) Lands $31 Million Clean Energy Contract On An Undervalued Narrative

Willdan Group (WLDN) secured a $31 million clean energy contract with Encina Wastewater Authority for a renewable cogeneration project. Despite recent stock price drops, the company shows strong long-term shareholder returns, and a popular valuation narrative suggests it is significantly undervalued. However, Simply Wall …

Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run

Celldex Therapeutics (CLDX) stock has seen a significant 59.5% return over the past year, leading to a valuation that appears expensive when considering market multiples and P/B ratio. The company's P/B ratio of 6.1x is higher than the broader biotech industry average, indicating a …

CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78

Leerink Partners has decreased its target price for Celldex Therapeutics Inc. from $78 to $70. This change was reported by Reuters two days prior to the crawl date, indicating a potential re-evaluation of the company's financial outlook by the analyst firm.

Alldigi Tech shares rise 3.51% as board set to consider Q1 results and interim dividend tomorrow

Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

This article provides an update on several biopharma companies. Summit Therapeutics has released new data for its cancer immunotherapy ivonescimab, which shows improved survival rates in lung cancer patients, addressing investor skepticism. Celldex Therapeutics' autoimmune drug barzolvolimab failed a mid-stage trial for prurigo nodularis …

Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68

Stifel has maintained its Buy rating on Celldex Therapeutics (CLDX.US) and reiterated a target price of $68. This indicates continued confidence from Stifel in the company's performance and future prospects.

Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss

Celldex maintains confidence in its drug barzolvolimab for Chronic Spontaneous Urticaria (CSU) despite a recent trial failure in Prurigo Nodularis. The company's stance follows a previous study miss for the drug in August 2025. This article highlights Celldex's continued commitment to barzolvolimab for CSU.

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex Therapeutics has discontinued its Phase 2 clinical trial for barzolvolimab in prur

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss

Celldex Therapeutics announced it is discontinuing the development of barzolvolimab for prurigo nodularis (PN) after the drug failed to meet primary and secondary endpoints in a Phase 2 trial. Despite the drug effectively depleting mast cells, it did not significantly improve itch or skin …

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside

Celldex Therapeutics, Inc. (CLDX) is a biopharmaceutical company specializing in treatments for inflammatory, allergic, and autoimmune diseases, boasting a market cap of $2.78 billion. Despite currently being unprofitable, indicated by a negative Forward P/E ratio, analysts forecast a 64.31% potential upside with an average …

Cantor Fitzgerald Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price

Celldex's Barzolvolimab Fails To Meet Key Goals In Phase 2 Study For Prurigo Nodularis; Stock Down

(RTTNews) - Celldex (CLDX) reported topline results from the Phase 2 study of Barzolvolimab in Prurigo Nodularis or PN, indicating that the study did not meet the primary endpoint and key secondary endpoints. Following the results, Celldex will discontinue the Phase 2 study in …

Celldex stock falls after phase 2 trial misses key endpoints By Investing.com

Celldex Therapeutics shares dropped 13% after the company announced that its Phase 2 study of barzolvolimab for prurigo nodularis failed to meet its primary and key secondary endpoints. Despite demonstrating profound mast cell depletion, the drug did not improve itch or skin lesions compared …

Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch

Celldex (NASDAQ: CLDX) announced that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) failed to meet its primary and key secondary endpoints, despite successfully depleting mast cells. The company is discontinuing the PN program based on these results, which suggested that mast …

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex reported that its Phase 2 study of barzolvolimab for prurigo nodularis (PN) did not meet its primary or key secondary efficacy endpoints, leading the company to discontinue the study for this indication. Despite profound mast cell depletion in PN patients, there was no …

Celldex to stop skin disease study after trial setback

Celldex Therapeutics announced it would discontinue development of its experimental drug barzolvolimab for prurigo nodularis after it failed to meet primary and secondary goals in a mid-stage study. This setback sent the company's shares down over 7% in extended trading. Despite the drug effectively …

Guggenheim raises Celldex stock price target on trial outlook By Investing.com

Guggenheim has increased its price target for Celldex Therapeutics (NASDAQ:CLDX) shares to $100 from $90, maintaining a Buy rating due to the promising outlook for its drug, barzolvolimab. The firm's analysis, ahead of the pivotal EMBARQ-CSU1/2 trial results expected in October 2026, projects approximately …

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

Morgan Stanley has revised its price target for Celldex Therapeutics (NASDAQ:CLDX) to $40, down from the previous $44. Despite this adjustment, the firm has decided to maintain its Overweight rating on the stock.

Alldigi Tech files Business Responsibility and Sustainability Report for FY26

Lloyds Banking Group (LSE:LLOY) Could Be 4% Below Fair Value On Sainsbury’s Banking Exit

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Lloyds Banking Group (LSE:LLOY) is back in focus after Sainsbury's completed its shift away from full-service banking, highlighting how incumbent UK banks may …